When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EW - Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Edwards Lifesciences Corporation
2024-02-14 13:27:48 ET
Summary
Edwards Lifesciences achieved 13% organic revenue growth and received FDA approval for their EVOQUE tricuspid valve replacement system.
The company plans to spin off its low-growth Critical Care business to focus on the rapidly expanding structural heart market.
Edwards Lifesciences anticipates revenue growth of 8 to 10 percent in FY24, driven by the launch of EVOQUE and efforts to secure national coverage determination for Medicare patients.